← Leaderboards
Fumito Ito
University Of Michigan At Ann Arbor
$4,464,058
Attributed
$7,009,852
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,009,852 · 6
By mechanism
R01$5,059,006 · 2
K08$874,800 · 1
R38$743,297 · 1
P30$332,749 · 2
Top collaborators
- Grace Dy4 shared
- Yun Wu4 shared
- Young-Kwon Hong2 shared
- Sanjeet Patel2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Pavan Reddy$35,237,005
- Kathleen A Cooney$10,810,865
- D. Keith Bishop$8,118,791
- Arul M Chinnaiyan$35,112,976
- Yusuke Shiozawa$3,431,923
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyMalignant NeoplasmsCellsAntigensFutureInterestPre-Clinical ModelImmuneCancer TherapyFoundationsMediatingResponseImmune Checkpoint InhibitorCessation Of LifeIn SituInsightSamplingImmunogenicityProteinsIn VivoImmune ResponseEffective TherapySolidTechnology
Grant awards (19)
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$1,236,637
R01 · FY2025 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors$392,779
R01 · FY2025 · CA · contact PI
USC Stimulating Access to Research in Residency (USC-StARR) Program$379,741
R38 · FY2025 · HL · contact PI
Flow Cytometry Core$217,268
P30 · FY2025 · CA · contact PI
Translational and Clinical Sciences$115,481
P30 · FY2025 · CA · contact PI
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$615,852
R01 · FY2024 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors$377,327
R01 · FY2024 · CA · contact PI
USC Stimulating Access to Research in Residency (USC-StARR) Program$363,556
R38 · FY2024 · HL · contact PI
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$630,231
R01 · FY2023 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors$400,868
R01 · FY2023 · CA · contact PI
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$592,674
R01 · FY2022 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors$402,417
R01 · FY2022 · CA · contact PI
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors$410,221
R01 · FY2021 · CA · contact PI
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells$174,960
K08 · FY2019 · CA · contact PI
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells$174,960
K08 · FY2018 · CA · contact PI
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells$174,960
K08 · FY2017 · CA · contact PI
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells$174,960
K08 · FY2016 · CA · contact PI
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells$132,754
K08 · FY2015 · CA · contact PI
Adoptive Cell Therapy with Rejuvenated Antigen-specific T Cells$42,206
K08 · FY2015 · CA · contact PI